Innovus Pharmaceuticals, Inc.
8845 Rehco Road
30 articles with Innovus Pharmaceuticals, Inc.
Innovus Pharma’s Product FlutiCare® Ranks #2 Behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray Categories
Company Places Additional Order of 220,000 Units to Meet Growing Demand
Innovus Pharma Announces the Approval and Launch of its OTC Hemorrhoid Xyralid® Suppositories in Canada
Xyralid®, Suppositories for the Reduction of Swelling and Inflammation of Hemorrhoidal Tissues, is the Ninth Innovus Pharma Product launched in Canada to Date
Innovus Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with a healthcare-dedicated institutional investor for the sale of 45,306,347 shares of common stock (or common stock equivalents), series A warrants to purchase up to 45,306,347 shares of common stock and series B warrants to purchase up to 45,306,347 shares of common stock in a private placement at a price of $0.07 per share and associated warrants for gross proceeds of approximately $3.17 million.
Innovus Pharma Announces All Cash Acquisition of All of the Assets of SupplementHunt.com, an E-Commerce Store with its Proprietary Sales Platform and Marketing Technology
Acquisition Currently Expected to Add $2 million in Revenue to Innovus Pharma on a Yearly Basis
Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin™ on Muscle Health in Adults in the United States
Clinical Study will be Completed and its Results Announced in the First Half of 2019
HealthiFeet®, Among the Products Acquired, Has Been a Proven Category Leader in Pilot Programs in Multiple Retail Stores
Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 Million for the Third Quarter 2018 and $19.2 Million for the First Nine Months of 2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, announced today its reported results for the third quarter 2018.
Innovus Pharmaceuticals to Release Its Third Quarter 2018 Financial Results on Wednesday, November 14, 2018
Innovus Pharmaceuticals, Inc., today announced that the Company will release its third quarter financial results on Wednesday, November 14, 2018.
Preliminary Quarterly Revenue Increase of 215-219% Comparable to 2017 Third Quarter
Innovus Pharma Receives Approval for Medicare Reimbursement for its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip Products
Innovus Pharmaceuticals, Inc. announced today that its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip products have become eligible for Medicare reimbursement.
First Product MZS Sleeping Aid™ Currently Expected to Launch in the U.S. in Q4 2018
Innovus Pharmaceuticals, Inc. today announced that Dr. Bassam Damaj, President & Chief Executive Officer, and Ryan Selhorn, Vice President, Chief Financial Officer, will present at the 2018 H.C. Wainwright 20th Annual Global Investment Conference
Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in Its 110 “Showcase” Retail Stores in the United States and Canada
Apeaz® is the Fifth Company Product to Be Sold in Retails Stores in the U.S. and Canada
Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax™
The Three Potential Products, If Approved, Will Supplement the Company’s Eight Products Launched in Canada to Date
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
Innovus Pharmaceuticals, Inc. announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets.
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products
Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million
SECFilings.com announces the publication of an article covering Innovus Pharmaceuticals Inc.
AllerVarx™ is the Ninth Innovus Pharma Product Launched in Canada to Date
Innovus Pharma Announces the Approval of Its Product ProstaGorx™ in Canada for Benign Prostatic Hyperplasia (“BPH”)
Innovus Pharmaceuticals, Inc. announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product (NPN #80085717) for the relief of urologic symptoms.